Infliximab and nephrotic syndrome

37Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Infliximab is a chimeric tumor necrosis factor-alpha (TNF-α) monoclonal antibody, which has been used extensively in patients with rheumatoid arthritis and inflammatory bowel disease. It also appears to be effective in other conditions such as psoriasis and ankylosing spondylitis. The major side effect of infliximab is infection. Renal complications are uncommon and not well recognized. This report describes a probable case of infliximab-induced membranous nephropathy. © The Author [2005]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Cite

CITATION STYLE

APA

Chin, G., Luxton, G., & Harvey, J. M. (2005). Infliximab and nephrotic syndrome. Nephrology Dialysis Transplantation, 20(12), 2824–2826. https://doi.org/10.1093/ndt/gfi180

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free